Given the widespread use of GLP‐1 agents and ongoing safety concerns, future research needs to study these drugs in breast cancer patients, critically evaluating their impact on cancer risk, recurrence, mortality, and long‐term outcomes for this population. The gene discussed is GLP1R; the disease is breast carcinoma.